All News

9 May 2012

Merck PETACC-8 Study of Erbitux as Adjuvant Treatment in Colon Cancer Shows no Benefit at Pre-specified Interim AnalysisAntibodies

9 May 2012

Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST (rilonacept) InjectionAntibodies

9 May 2012

Thallion and LFB Report Positive Top-Line Results from the Phase II SHIGATEC Trial at ‘VTEC 2012’Antibodies

8 May 2012

biOasis Transcend Vector Delivers an Anti-Amyloid Beta (AB) Antibody To The BrainAntibodies

8 May 2012

Millennium and Seattle Genetics Initiate Global Phase 3 Trial of ADCETRIS™ in Patients with CD30-Expressing Relapsed Cutaneous T-cell LymphomaAntibodies

7 May 2012

Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403Antibodies

3 May 2012

FibroGen Announces Promising Preliminary Data from an Open-label Phase 2 Study to Evaluate the Safety and Efficacy of FG-3019 in Individuals with Idiopathic Pulmonary Fibrosis (IPF) and Provides Program UpdateAntibodies

3 May 2012

Genentech Reports Positive Study of ACTEMRA Given by Subcutaneous InjectionAntibodies

2 May 2012

Two-Year Results Confirm Strong Efficacy of Two Drugs in Treatment of Age-Related Macular DegenerationAntibodies

2 May 2012

AVEO Announces Preliminary Results of Exploratory Phase 2 Study Evaluating HGF Inhibitor in First-Line Patients with Advanced Lung CancerAntibodies

27 April 2012

Baxter Presents Efficacy and Safety Data Evaluating GAMMAGARD LIQUID for Multifocal Motor Neuropathy at AAN Annual MeetingAntibodies

27 April 2012

Amgen Receives Complete Response Letter From FDA for XGEVA sBLA for Prevention of Bone MetastasesAntibodies

26 April 2012

Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC StudyAntibodies

26 April 2012

Complix’ Alphabody Protein Therapeutics Demonstrate Activity against both Undruggable Extracellular and Intracellular Disease TargetsAntibodies

25 April 2012

Nanobody for Alzheimer’s Disease From The Alliance With Boehringer Ingelheim Moves Closer Towards Phase I Clinical TrialsAntibodies

25 April 2012

Significant Improvement in Disability Scores Observed in Multiple Sclerosis Patients Who Received LemtradaTM* (Alemtuzumab) Compared With Rebif in Phase III TrialAntibodies

24 April 2012

Biotest consolidates its outstanding position in the hepatitis B hyperimmunoglobulin market with the marketing authorisation of Fovepta and with the initial sales of Hepatect in BrazilAntibodies

17 April 2012

ImmunoGen, Inc. Announces the IND Is Now Active for Its Folate-Receptor Targeting Anticancer Compound, IMGN853Antibodies

17 April 2012

ImmunoGen, Inc. Initiates Phase I Trial in Non-Hodgkin’s Lymphoma with Its Novel IMGN529 Anticancer CompoundAntibodies

16 April 2012

Morphotek, Inc. Announces Initiation of MORAb-004 Phase 2 Study in Metastatic Colorectal CancerAntibodies

16 April 2012

Baxter and Halozyme Provide Update on HyQ Biologics License ApplicationAntibodies

16 April 2012

Cimzia (certolizumab pegol) shows positive top-line phase 3 results in axial spondyloarthritis and ankylosing spondylitisAntibodies

13 April 2012

Biotest announces clinical trial data for its new investigational Intravenous Immunoglobulin (IVIG) product for the US marketAntibodies

12 April 2012

Abbott’s HUMIRA (adalimumab) Approved in Europe for Treatment of Ulcerative Colitis (UC)Antibodies

10 April 2012

iBio Announces Production of Biosimilar Palivizumab with its iBioLaunch™ TechnologyAntibodies

5 April 2012

Sanofi and Regeneron Announce Regulatory and Clinical Update for ZALTRAP (aflibercept)Antibodies

4 April 2012

Trillium provides update on anti-CD47 cancer programAntibodies

4 April 2012

Immunomedics Develops Novel Agents Targeting Renal Cell CarcinomaAntibodies

4 April 2012

Seattle Genetics Demonstrates Continued Leadership in Antibody-Drug Conjugates at AACRAntibodies

4 April 2012

Ablynx’s Partner Shows That a Nanobody Can Elicit Superior Anti-Tumour Efficacy Compared to Conventional Monoclonal Antibody ApproachesAntibodies

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Competitor Analysis: Complement C5 Inhibitors & C5 Receptor Antagonists

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

Report Package: Bispecific Antibodies

RNA-Targeted Novel Drug Modalities Based on RNA Editing, Epitranscriptomics, Direct RNA Targeting, Splicing Modulation, Translation Regulation, lncRNA & regRNA Targeting & More: a landscape analysis of technologies, targets, business and financing from an industry perspective

Ustekinumab (Stelara) Biosimilars Pipeline Review

CD38-Targeted Antibody & Cell Therapy Pipeline Review

Cadherin 17: A target opportunity to develop effector-enhanced drug modalities

Report Package: “Drug the Undruggable” Technologies

Tocilizumab (Actemra/RoActemra) Biosimilar Antibody Pipeline Review

PD-L1 x 4-1BB (CD137) Bispecific Antibody Pipeline Review